Evolution of COVID-19 patients treated with a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centred, retrospective cohort study

Although a vast knowledge has already been gathered on the pathophysiology of COVID-19, there are still limited, non-optimal treatment options. In this paper, we describe a multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated with ImmunoFormulation (IF), an add-on therapy developed to decrease duration of clinical symptoms. In parallel, a group of patients that did not receive IF was used for comparison (using standard of care treatment). A total of 39 patients were evaluated. Throughout the observational period, 90% of patients recovered in the IF cohort and 47.4% in the Control cohort (p=0.0057). From the symptoms with statistically significant differences, the duration of symptoms (i.e., the time to recover from it) was shorter in the IF cohort than in control cohort (in days, average), especially for fever (2.25 x 21.78), dry cough (4.38 x 24.00), dyspnoea (3.67 x 20.00), headache (2.00 x 26.50), diarrhoea (5.25 x 25.25), and weakness (1.92 x 23.30). This demonstrates a potential promising role of IF as adjuvant therapy on the evolution of symptomatology to COVID-19 patients.

Evolution of COVID-19 patients treated with ImmunoFormulation, a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centred, retrospective cohort study

10.21203/rs.3.rs-133532/v2 ◽

2021 ◽

Author(s):

Mariana Hernández ◽

Jully Urrea ◽

Luciano Bascoy

Keyword(s):

Retrospective Cohort ◽

Adverse Reactions ◽

Clinical Symptoms ◽

Treatment Options ◽

Standard Of Care ◽

Control Cohort ◽

Observational Period ◽

Duration Of Symptoms ◽

Abstract Background Although a vast knowledge has already been gathered on the pathophysiology of COVID-19, there are still limited, non-optimal treatment options. In this context, agents that can act on prophylaxis or as adjuvants to the therapies are of high value.Methods In this paper, we describe a multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated with ImmunoFormulation (IF), an add-on therapy developed to decrease duration of clinical symptoms. In parallel, a group of patients that did not receive IF was used for comparison (using standard of care treatment). A total of 39 patients were evaluated for their recovery rate, general symptoms and their severity, and adverse reactions.Results Throughout the observational period, 90% of patients recovered in the IF cohort and 47.4% in the Control cohort (p=0.0057). From the symptoms with statistically significant differences, the duration of symptoms (i.e., the time to recover from it) was shorter in the IF cohort than in control cohort (in days, average), especially for fever (2.25 x 21.78), dry cough (4.38 x 24.00), dyspnoea (3.67 x 20.00), headache (2.00 x 26.50), diarrhoea (5.25 x 25.25), and weakness (1.92 x 23.30).Conclusions This demonstrates a potential promising role of IF as adjuvant therapy on the evolution of symptomatology to COVID-19 patients.

Evolution of COVID-19 Patients Treated With ImmunoFormulation, a Combination of Nutraceuticals to Reduce Symptomatology and Improve Prognosis: a Multi-centred, Retrospective Cohort Study

10.21203/rs.3.rs-133532/v1 ◽

2020 ◽

Author(s):

Mariana Díaz Hernández ◽

Jully Urrea ◽

Luciano Bascoy

Keyword(s):

Retrospective Cohort ◽

Adverse Reactions ◽

Clinical Symptoms ◽

Treatment Options ◽

Standard Of Care ◽

Control Cohort ◽

Observational Period ◽

Duration Of Symptoms ◽

Abstract BackgroundAlthough a vast knowledge has already been gathered on the pathophysiology of COVID-19, there are still limited, non-optimal treatment options. In this context, agents that can act on prophylaxis or as adjuvants to the therapies are of high value.MethodsIn this paper, we describe a multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated with ImmunoFormulation (IF), an add-on therapy developed to decrease duration of clinical symptoms. In parallel, a group of patients that did not receive IF was used for comparison (using standard of care treatment). A total of 39 patients were evaluated for their recovery rate, general symptoms and their severity, and adverse reactions.ResultsThroughout the observational period, 90% of patients recovered in the IF cohort and 47.4% in the Control cohort (p=0.0057). From the symptoms with statistically significant differences, the duration of symptoms (i.e., the time to recover from it) was shorter in the IF cohort than in control cohort (in days, average), especially for fever (2.25 x 21.78), dry cough (4.38 x 24.00), dyspnoea (3.67 x 20.00), headache (2.00 x 26.50), diarrhoea (5.25 x 25.25), and weakness (1.92 x 23.30).ConclusionsThis demonstrates a potential promising role of IF as adjuvant therapy on the evolution of symptomatology to COVID-19 patients.

Evolution of COVID-19 patients treated with a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centred, retrospective cohort study

Journal of Clinical Review & Case Reports ◽

10.33140/jcrc.06.07.01 ◽

2021 ◽

Vol 6 (7) ◽

Keyword(s):

Retrospective Cohort ◽

Adverse Reactions ◽

Clinical Symptoms ◽

Treatment Options ◽

Standard Of Care ◽

Control Cohort ◽

Observational Period ◽

Duration Of Symptoms ◽

Although a vast knowledge has already been gathered on the pathophysiology of COVID-19, there are still limited, non-optimal treatment options. In this context, agents that can act on prophylaxis or as adjuvants to the therapies are of high value. In this paper, we describe a multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated with Immuno Formulation (IF), an add-on therapy developed to decrease duration of clinical symptoms. In parallel, a group of patients that did not receive IF was used for comparison (using standard of care treatment). A total of 39 patients were evaluated for their recovery rate, general symptoms and their severity, and adverse reactions. Throughout the observational period, 90% of patients recovered in the IF cohort and 47.4% in the Control cohort (p=0.0057). From the symptoms with statistically significant differences, the duration of symptoms (i.e., the time to recover from it) was shorter in the IF cohort than in control cohort (in days, average), especially for fever (2.25 x 21.78), dry cough (4.38 x 24.00), dyspnoea (3.67 x 20.00), headache (2.00 x 26.50), diarrhoea (5.25 x 25.25), and weakness (1.92 x 23.30). This demonstrates a potential promising role of IF as adjuvant therapy on the evolution of symptomatology to COVID-19 patients.

TNS1- ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma

Acta Medica Academica ◽

10.5644/ama2006-124.248 ◽

2019 ◽

Vol 48 (1) ◽

pp. 116

Author(s):

Jessica Lee ◽

Arun Singh ◽

Siraj M. Ali ◽

Douglas I. Lin ◽

Samuel J. Klempner

Keyword(s):

Clinical Care ◽

Treatment Options ◽

Standard Of Care ◽

Genomic Profiling ◽

Curative Intent ◽

Case Identification ◽

Complementary Role ◽

Comprehensive Genomic Profiling ◽

Objective. We report a female patient diagnosed with a leiomyosarcoma and who harbored a druggable target as identified by comprehensive genomic profiling in the course of clinical care.Case Report. The patient progressed five years after curative intent surgery and adjuvant treatment. After failure of multiple lines of chemotherapy,she was enrolled in a trial of an ALK inhibitor based on comprehensive genomic profiling (CGP) identifying an TNS1-ALK fusion.Conclusion. In this case, identification of the ALK kinase fusion permitted enrollment in a matched mechanism driven clinical trial after exhausting standard of care treatment options. CGP raises the possibility of uterine inflammatory myofibroblastic tumor as an alternative diagnosisto leiomyosarcoma, highlighting the complementary role of CGP beyond immunohistochemical analyses.

Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy

Future Oncology ◽

10.2217/fon-2020-0720 ◽

2020 ◽

Author(s):

Deeksha G Lahori ◽

Pegah Varamini

Keyword(s):

Immune Checkpoint ◽

Checkpoint Inhibitors ◽

Treatment Options ◽

Standard Of Care ◽

Immune Checkpoint Blockade ◽

Checkpoint Blockade ◽

Standard Of Care Treatment ◽

Anticancer Treatment ◽

Novel Strategy

In recent years, cancer immunotherapy has evolved as an exciting novel strategy for researchers and clinicians worldwide. Immunotherapeutic agents such as immune checkpoint blockers have changed the standard-of-care treatment provided for many tumors. Unfortunately, only a small proportion of patients respond effectively to these checkpoint inhibitors. Moreover, the immunosuppressive pathways for cancer are probably too complicated to achieve optimal outcome with immune checkpoint inhibitors alone. Combining current therapeutic options and immunotherapy-based approaches is being explored as an effective strategy to treat cancer. The use of nanotechnology-based platforms for delivery of immunotherapeutic agents or combination therapy could offer a major advantage over conventional anticancer treatment options. This review highlights the potential role of different nanotechnology-based strategies in improving the efficacy of immune checkpoint blockade therapy.

352P The role of radiotherapy in early-stage primary diffuse large B-cell lymphoma of the Waldeyer's Ring: A retrospective cohort study

Annals of Oncology ◽

10.1016/s0923-7534(21)00510-x ◽

2016 ◽

Vol 27 ◽

pp. ix110

Author(s):

S.F. Lee

Keyword(s):

Cohort Study ◽

Retrospective Cohort ◽

Cell Lymphoma ◽

Early Stage ◽

B Cell Lymphoma ◽

Waldeyer’S Ring ◽

Large B Cell Lymphoma ◽

Large B Cell

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer

Therapeutic Advances in Gastroenterology ◽

10.1177/17562848211024460 ◽

2021 ◽

Vol 14 ◽

pp. 175628482110244

Author(s):

Vanessa Wookey ◽

Axel Grothey

Keyword(s):

Colorectal Cancer ◽

Immune Checkpoint ◽

Checkpoint Inhibitors ◽

Treatment Options ◽

Standard Of Care ◽

Cancer Type ◽

Cancer Therapies ◽

Multiple Cancer ◽

Multiple Treatment

Colorectal cancer (CRC) is the third most common cancer type in both men and women in the USA. Most patients with CRC are diagnosed as local or regional disease. However, the survival rate for those diagnosed with metastatic disease remains disappointing, despite multiple treatment options. Cancer therapies for patients with unresectable or metastatic CRC are increasingly being driven by particular biomarkers. The development of various immune checkpoint inhibitors has revolutionized cancer therapy over the last decade by harnessing the immune system in the treatment of cancer, and the role of immunotherapy continues to expand and evolve. Pembrolizumab is an anti-programmed cell death protein 1 immune checkpoint inhibitor and has become an essential part of the standard of care in the treatment regimens for multiple cancer types. This paper reviews the increasing evidence supporting and defining the role of pembrolizumab in the treatment of patients with unresectable or metastatic CRC.

Sa1014 Role of Proton Pump Inhibitors in the Development of Spontaneous Bacterial Peritonitis Amongst Cirrhotics; a Retrospective Cohort Study

Gastroenterology ◽

10.1016/s0016-5085(12)63667-1 ◽

2012 ◽

Vol 142 (5) ◽

pp. S-946 ◽

Cited By ~ 4

Author(s):

Anupam Aditi ◽

Jeffrey S. Crippin ◽

Ankur Abhishek

Keyword(s):

Cohort Study ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Retrospective Cohort ◽

Spontaneous Bacterial Peritonitis ◽

Bacterial Peritonitis

Role of quality measurement in inappropriate use of screening for colorectal cancer: retrospective cohort study

BMJ ◽

10.1136/bmj.g1247 ◽

2014 ◽

Vol 348 (feb26 2) ◽

pp. g1247-g1247 ◽

Cited By ~ 30

Author(s):

S. D. Saini ◽

S. Vijan ◽

P. Schoenfeld ◽

A. A. Powell ◽

S. Moser ◽

...

Keyword(s):

Colorectal Cancer ◽

Cohort Study ◽

Retrospective Cohort ◽

Quality Measurement ◽

Inappropriate Use

Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study

BMC Endocrine Disorders ◽

10.1186/s12902-021-00850-2 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Maryam Dehghani ◽

Zahra Davoodi ◽

Farahnaz Bidari ◽

Amin Momeni Moghaddam ◽

Davood Khalili ◽

...

Keyword(s):

Growth Hormone ◽

Cohort Study ◽

Cavernous Sinus ◽

Pituitary Adenomas ◽

Retrospective Cohort ◽

Remission Rate ◽

Cavernous Sinus Invasion ◽

Dual Staining

Abstract Background Regarding the inconclusive results of previous investigations, this study aimed to determine the association between pathology, as a possible predictor, with remission outcomes, to know the role of pathology in the personalized decision making in acromegaly patients. Methods A retrospective cohort study was performed on the consecutive surgeries for growth hormone (GH) producing pituitary adenomas from February 2015 to January 2021. Seventy-one patients were assessed for granulation patterns and prolactin co-expression as dual staining adenomas. The role of pathology and some other predictors on surgical remission was evaluated using logistic regression models. Results Among 71 included patients, 34 (47.9%) patients had densely granulated (DG), 14 (19.7%) had sparsely granulated (SG), 23 (32.4%) had dual staining pituitary adenomas. The remission rate was about 62.5% in the patients with SG and DG adenomas named single staining and 52.2% in dual staining groups. Postoperative remission was 1.53-folds higher in the single staining adenomas than dual staining-one (non-significant). The remission rate was doubled in DG group compared to two other groups (non-significant). By adjusting different predictors, cavernous sinus invasion and one-day postoperative GH levels decreased remission rate by 91% (95% CI: 0.01–0.67; p = 0.015) and 64% (95% CI: 0.19–0.69; p < 0.001), respectively. Responses to the medications were not significantly different among three groups. Conclusion Various pathological subtypes of pituitary adenomas do not appear to have a predictive role in estimating remission outcomes. Cavernous sinus invasion followed by one-day postoperative GH is the strongest parameter to predict biochemical remission.